How the UK’s rollback of banking regulations could risk another financial crisis 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
South Korea Weighs AI Profit Sharing as Samsung and SK Hynix Earnings Surge 
Why your retirement fund might soon include cryptocurrency 
SoftBank Eyes Up to $25B OpenAI Investment Amid AI Boom 
China's Refining Industry Faces Major Shakeup Amid Challenges 
Gold Prices Rise as Markets Await Trump’s Policy Announcements 
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand 
Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
SpaceX Sets IPO Price at $135 Per Share Ahead of Historic Nasdaq Debut 
UK Markets Face Rising Volatility as Hedge Funds Target Pound and Gilts 
Switch Eyes Multi-Billion-Dollar Funding Round at $50 Billion Valuation Ahead of Potential IPO 
CBS News Fires Scott Pelley Amid Major Changes at ‘60 Minutes’ in 2026 
Do investment tax breaks work? A new study finds the evidence is ‘mixed at best’ 
Meta Challenges Australia’s Proposed Tech Tax, Citing U.S. Trade Agreement Concerns 
Infosys Shares Drop Amid Earnings Quality Concerns 
Jensen Huang Strengthens Nvidia’s South Korea Ties Amid AI Expansion 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
